06/02/2026 Momelotinib for treating myelofibrosis in patients with moderate to severe anaemia
The Ministry of Health’s Drug Advisory Committee has recommended:
- Momelotinib 100 mg, 150 mg and 200 mg tablets for treating myelofibrosis-related splenomegaly or symptoms in patients with moderate to severe anaemia.
Funding status
RMomelotinib 100 mg, 150 mg and 200 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2026.
Clinical indication, subsidy class and MediShield Life claim limit for momelotinib are provided in the Annex.